Abstract
Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide and the incidence and mortality rate are nearly identical in the United States. The Milan Criteria established thresholds of tumor size and number as predictors of optimum overall survival with liver transplant and changed the definitive treatment for HCC. However, after nearly two decades of experience two problems have emerged: post-transplant recurrence continues and an increasing number of patients exceed these size criteria. While tumor burden is an important prognostic factor, it remains limited in its ability to fully define underlying tumor biology and predict recurrence after transplant. Recognizing that tumor size and number are merely surrogate markers of tumor behavior, multiple centers have sought to expand these criteria and consider other oncologic and radiologic factors. Response to locoregional therapies may help to better determine tumor behavior and predict which patients might recur after transplant. Emerging analysis of tumor biology and genetics may also help to predict recurrence more accurately than size alone. Future selection of transplant candidates may be via molecular profiling or chronological imaging changes to identify those patients who would benefit most from the finite number of available grafts, while limiting recurrence after transplant.
Keywords: Hepatocellular carcinoma, transplant, prognosis.
Current Cancer Therapy Reviews
Title:Hepatocellular Carcinoma Outside of the Milan Criteria
Volume: 10 Issue: 3
Author(s): C. Anne Doughtie, Michael E. Egger, Kean O. Feyzeau, Christopher M. Jones, Michael R. Marvin, Kelly M. McMasters and Eric G. Davis
Affiliation:
Keywords: Hepatocellular carcinoma, transplant, prognosis.
Abstract: Hepatocellular carcinoma (HCC) is a leading cause of cancer deaths worldwide and the incidence and mortality rate are nearly identical in the United States. The Milan Criteria established thresholds of tumor size and number as predictors of optimum overall survival with liver transplant and changed the definitive treatment for HCC. However, after nearly two decades of experience two problems have emerged: post-transplant recurrence continues and an increasing number of patients exceed these size criteria. While tumor burden is an important prognostic factor, it remains limited in its ability to fully define underlying tumor biology and predict recurrence after transplant. Recognizing that tumor size and number are merely surrogate markers of tumor behavior, multiple centers have sought to expand these criteria and consider other oncologic and radiologic factors. Response to locoregional therapies may help to better determine tumor behavior and predict which patients might recur after transplant. Emerging analysis of tumor biology and genetics may also help to predict recurrence more accurately than size alone. Future selection of transplant candidates may be via molecular profiling or chronological imaging changes to identify those patients who would benefit most from the finite number of available grafts, while limiting recurrence after transplant.
Export Options
About this article
Cite this article as:
Doughtie C. Anne, E. Egger Michael, O. Feyzeau Kean, M. Jones Christopher, R. Marvin Michael, M. McMasters Kelly and G. Davis Eric, Hepatocellular Carcinoma Outside of the Milan Criteria, Current Cancer Therapy Reviews 2014; 10 (3) . https://dx.doi.org/10.2174/157339471003150212112046
DOI https://dx.doi.org/10.2174/157339471003150212112046 |
Print ISSN 1573-3947 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6301 |
Call for Papers in Thematic Issues
Current progress in Protein Degradation and Cancer Therapy
argeted Protein Degradation is gaining momentum in cancer therapy, it facilitate targeting undruggable proteins, it overcome cancer resistance and avoid undesirable side effects. Thus small molecules degraders have emerged as novel therapeutic strategy. Targeted protein degradation (TPD), the process of eliminating a protein of interest hold a great promise for ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Patents Related to Cancer Stem Cell Research
Recent Patents on DNA & Gene Sequences Tumor Targeted Therapies: Strategies for Killing Cancer but not Normal Cells
Current Cancer Therapy Reviews Low Molecular Weight and Oligomeric Chitosans and Their Bioactivities
Current Topics in Medicinal Chemistry 3-Bromopyruvate: A New Targeted Antiglycolytic Agent and a Promise for Cancer Therapy
Current Pharmaceutical Biotechnology Telomerase Inhibitors: Potential Anticancer Agents
Mini-Reviews in Organic Chemistry Heparin, Heparan Sulfate and Heparanase in Cancer: Remedy for Metastasis?
Anti-Cancer Agents in Medicinal Chemistry Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B
Current Topics in Medicinal Chemistry Targeted Delivery of Tumor Suppressor microRNA-1 by Transferrin- Conjugated Lipopolyplex Nanoparticles to Patient-Derived Glioblastoma Stem Cells
Current Pharmaceutical Biotechnology Recent Developments in Nanomedicines for Management of Various Health Issues Via Metabolism and Physico-Chemical Properties
Current Drug Metabolism Proteomic Approaches for the Study of Transgelins as Tumor-associated Proteins and Potential Biomarkers
Current Proteomics Computational Approach to the Discovery of Phytochemical Molecules with Therapeutic Potential Targets to the PKCZ protein
Letters in Drug Design & Discovery Recent Patents of Gene Sequences Relative to the Phosphatidylinositol 3-kinase / Akt Pathway and their Relevance to Drug Discovery
Recent Patents on DNA & Gene Sequences Transcriptional Regulation of mPGES1 in Cancer: An Alternative Approach to Drug Discovery?
Current Drug Targets Recent Patents on Liposomal-Based Chemotherapeutics with a Triggered Release Mechanism
Recent Patents on Nanomedicine Identification of Critical MicroRNA Gene Targets in Cervical Cancer Using Network Properties
MicroRNA Rational Design, Synthesis and Biological Evaluation of Novel Derivatives Based on in vivo Metabolism of Natural Product β-elemene
Letters in Drug Design & Discovery Oncomirs: From Tumor Biology to Molecularly Targeted Anticancer Strategies
Mini-Reviews in Medicinal Chemistry Renin-angiotensin System Inhibitors and Development of Hepatocellular Carcinoma: A Systematic Review and Meta-analysis
Current Pharmaceutical Design Blood-Brain Barrier and Breast Cancer Resistance Protein: A Limit to the Therapy of CNS Tumors and Neurodegenerative Diseases
Anti-Cancer Agents in Medicinal Chemistry Fungal Biotechnology of the Red Sea Alga Sarggassum subrepandum with Potential of Anticancer and Anti-Hepatitis C Virus Protease Activities
Letters in Organic Chemistry